Tag: infuenza business
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Data-rich or data-poor: Where should manufacturers focus their AI efforts?
Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.
